Tang Lab

Laboratory of Biomaterials for Immunoengineering

Personalized cancer vaccines

See more

The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials. EPFL researchers are currently working on an alternative. They have developed a platform that allows a cancer vaccine to be delivered to a precise location and stimulate the immune system in a safe way – thereby overcoming one of the two obstacles to creating an effective vaccine.

Our research

The overarching goal of Tang laboratory is to establish the detailed understanding of the interactions between synthetic biomaterials and the immune system so that we can precisely modulate the immune response using engineered intelligent biomaterials for effective and safe immunotherapies for cancer, infectious diseases, and autoimmune disorders. We leverage the power of state-of-the-art synthetic chemistry, materials science and nanotechnology to advance the diagnosis and therapy of human diseases. The ultimate goal is to translate new materials and technologies for clinical applications. There are three major components in our research program: 1) design and syntheses of novel organic or inorganic biocompatible biomaterials with highly controlled properties for immunoengineering; 2) study of the interdependent interactions between synthetic biomaterials/nanomedicines and the biological system, in particular, the immune system; 3) control of the biophysicochemical properties of biomaterials to precisely modulate the immune responses to treat cancer and other diseases.

Contact

Head of Laboratory : Li Tang
EPFL-STI-IBI/IMX-LBI
MED 1 2826, Station 9
CH-1015 Lausanne, Switzerland
Phone : 41 21 693 0937
Email: [email protected]


Administrative Assistant : Monica Navarro Suarez
EPFL-STI-IBI/IMX-LBI
MED 1 2726, Station 9
CH-1015 Lausanne, Switzerland
Phone : 41 21 693 0756
Email: [email protected]